BIOATLA, INC. Lease, Cost
BIOATLA, INC. (BCAB) reported Lease, Cost of $447.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-13
- BIOATLA, INC. lease, cost for the quarter ending 2026-06-30 was $447.00K, a 18.13% decline year-over-year.
- BIOATLA, INC. lease, cost for the quarter ending 2026-03-31 was $478.00K, a 8.39% increase year-over-year.
- BIOATLA, INC. lease, cost for the quarter ending 2025-12-31 was $446.00K, a 6.19% increase year-over-year.
- BIOATLA, INC. lease, cost for the quarter ending 2025-09-30 was $446.00K, a 6.19% increase year-over-year.
- BIOATLA, INC. lease, cost for fiscal 2025 was $1.88M, a 8.49% increase from fiscal 2024.
- BIOATLA, INC. lease, cost for fiscal 2024 was $1.73M, a 9.14% increase from fiscal 2023.
- BIOATLA, INC. lease, cost for fiscal 2023 was $1.59M, a 5.59% increase from fiscal 2022.
- BIOATLA, INC. lease, cost for fiscal 2022 was $1.50M, a 3.34% decline from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 6 month as first filed | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $447.00K 10-Q · filed 2026-08-13 | $925.00K 10-Q · filed 2026-08-13 | $1.37M derived: sum of 3 quarters · filed 2026-08-13 | $1.82M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $478.00K 10-Q · filed 2026-05-15 | $924.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.37M derived: sum of 3 quarters · filed 2026-05-15 | $1.92M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $446.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $892.00K derived: sum of 2 quarters · filed 2026-03-31 | $1.44M derived: sum of 3 quarters · filed 2026-08-13 | $1.88M 10-K · filed 2026-03-31 | |
| 2025-09-30 | $446.00K 10-Q · filed 2025-11-13 | $992.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.43M 10-Q · filed 2025-11-13 | $1.85M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $546.00K 10-Q · filed 2026-08-13 | $987.00K 10-Q · filed 2026-08-13 | $1.41M derived: sum of 3 quarters · filed 2026-08-13 | $1.83M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $441.00K 10-Q · filed 2026-05-15 | $861.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.28M derived: sum of 3 quarters · filed 2026-05-15 | $1.75M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $420.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $840.00K derived: sum of 2 quarters · filed 2026-03-31 | $1.31M derived: sum of 3 quarters · filed 2026-03-31 | $1.73M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $420.00K 10-Q · filed 2025-11-13 | $892.00K derived: sum of 2 quarters · filed 2025-11-13 | $1.31M 10-Q · filed 2025-11-13 | $1.72M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $472.00K 10-Q · filed 2025-08-07 | $892.00K 10-Q · filed 2025-08-07 | $1.30M derived: sum of 3 quarters · filed 2025-08-07 | $1.70M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $420.00K 10-Q · filed 2025-05-06 | $824.00K derived: sum of 2 quarters · filed 2025-05-06 | $1.23M derived: sum of 3 quarters · filed 2025-05-06 | $1.60M derived: sum of 4 quarters · filed 2025-05-06 | |
| 2023-12-31 | $404.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $812.00K derived: sum of 2 quarters · filed 2025-03-28 | $1.18M derived: sum of 3 quarters · filed 2025-03-28 | $1.59M 10-K · filed 2025-03-28 | |
| 2023-09-30 | $408.00K 10-Q · filed 2024-11-07 | $776.00K derived: sum of 2 quarters · filed 2024-11-07 | $1.18M 10-Q · filed 2024-11-07 | $1.58M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $368.00K 10-Q · filed 2024-08-08 | $775.00K 10-Q · filed 2024-08-08 | $1.17M derived: sum of 3 quarters · filed 2024-08-08 | $1.56M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $408.00K 10-Q · filed 2024-05-14 | $801.00K derived: sum of 2 quarters · filed 2024-05-14 | $1.19M derived: sum of 3 quarters · filed 2024-05-14 | $1.52M derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | $393.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $786.00K derived: sum of 2 quarters · filed 2024-03-26 | $1.11M derived: sum of 3 quarters · filed 2024-03-26 | $1.50M 10-K · filed 2024-03-26 | |
| 2022-09-30 | $393.00K 10-Q · filed 2023-11-07 | $718.00K derived: sum of 2 quarters · filed 2023-11-07 | $1.11M 10-Q · filed 2023-11-07 | $1.50M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-06-30 | $325.00K 10-Q · filed 2023-08-01 | $777.00K 10-Q · filed 2023-08-01 | $717.00K 10-Q · filed 2022-08-09 | $1.11M derived: sum of 3 quarters · filed 2023-08-01 | $1.50M derived: sum of 4 quarters · filed 2023-08-01 |
| 2022-03-31 | $393.00K 10-Q · filed 2023-05-11 | $782.00K derived: sum of 2 quarters · filed 2023-05-11 | $1.17M derived: sum of 3 quarters · filed 2023-05-11 | $1.56M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $389.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $778.00K derived: sum of 2 quarters · filed 2023-03-23 | $1.17M derived: sum of 3 quarters · filed 2023-03-23 | $1.55M 10-K · filed 2023-03-23 | |
| 2021-09-30 | $389.00K 10-Q · filed 2022-11-04 | $778.00K derived: sum of 2 quarters · filed 2022-11-04 | $1.17M 10-Q · filed 2022-11-04 | ||
| 2021-06-30 | $389.00K 10-Q · filed 2022-08-09 | $777.00K 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | $389.00K 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |